GlobeNewswire Inc | Nov 10, 2021 08:30AM EST

November 10, 2021

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Companys management team will be presenting at the following investor conferences:

-- Jefferies London Healthcare ConferenceWednesday, November 17 at 11:20 a.m. GMT / 6:20 a.m. ET

-- Piper Sandler 33rd Annual Virtual Healthcare ConferenceA pre-recorded fireside chat will be available on-demand beginning on Monday, November 22 at 10:00 a.m. ET

The webcasts of the presentations will be accessible from the Media & Investors page of Albireos website, ir.albireopharma.com. To ensure a timely connection to the live Jefferieswebcast, it is recommended that users register at least 15 minutes prior to the scheduled start times. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireos website for 30 days following the event.

About AlbireoAlbireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireos lead product, Bylvay(odevixibat), was approved by the U.S. FDA as the first drug for the treatment of pruritusin patients 3 months of age and older in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFICin patients 6 months or older and has been submitted for pricing and reimbursement approval. The Company is progressing a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:Colleen Alabiso, 857-356-3905,colleen.alabiso@albireopharma.comLauren Sneider, 857-300-1737,lauren.sneider@albireopharma.com

Investor Contact:Hans Vitzthum, LifeSci Advisors, LLC.,617-430-7578